- Home
- BRZE vs ZLAB Comparison
BRZE vs ZLAB Comparison
Compare BRZE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRZE
- ZLAB
- Stock Information
- Founded
- BRZE 2011
- ZLAB 2013
- Country
- BRZE United States
- ZLAB China
- Employees
- BRZE N/A
- ZLAB N/A
- Industry
- BRZE Computer Software: Prepackaged Software
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- BRZE Technology
- ZLAB Health Care
- Exchange
- BRZE Nasdaq
- ZLAB Nasdaq
- Market Cap
- BRZE 3.6B
- ZLAB 3.0B
- IPO Year
- BRZE 2021
- ZLAB 2017
- Fundamental
- Price
- BRZE $44.31
- ZLAB $26.72
- Analyst Decision
- BRZE Strong Buy
- ZLAB Strong Buy
- Analyst Count
- BRZE 20
- ZLAB 3
- Target Price
- BRZE $54.30
- ZLAB $55.00
- AVG Volume (30 Days)
- BRZE 1.9M
- ZLAB 761.7K
- Earning Date
- BRZE 12-09-2024
- ZLAB 11-12-2024
- Dividend Yield
- BRZE N/A
- ZLAB N/A
- EPS Growth
- BRZE N/A
- ZLAB N/A
- EPS
- BRZE N/A
- ZLAB N/A
- Revenue
- BRZE $563,967,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- BRZE $27.28
- ZLAB $48.50
- Revenue Next Year
- BRZE $16.96
- ZLAB $47.37
- P/E Ratio
- BRZE N/A
- ZLAB N/A
- Revenue Growth
- BRZE 28.31
- ZLAB 35.01
- 52 Week Low
- BRZE $29.18
- ZLAB $13.48
- 52 Week High
- BRZE $61.53
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- BRZE 68.44
- ZLAB 46.04
- Support Level
- BRZE $42.67
- ZLAB $25.71
- Resistance Level
- BRZE $45.78
- ZLAB $27.49
- Average True Range (ATR)
- BRZE 2.26
- ZLAB 1.07
- MACD
- BRZE 0.07
- ZLAB -0.17
- Stochastic Oscillator
- BRZE 74.35
- ZLAB 21.54
About BRZE Braze Inc.
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates a majority of its revenue from the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.